-30%

est. 2Y upside i

Series A

DNA App Store

Rank

#3970

Sector

Consumer Genomics

Est. Liquidity

~6Y

Data Quality

Data: Low

This equity offer carries extreme structural risk and is highly unlikely to generate meaningful returns within a 2-year horizon.

Last updated: May 14, 2026

Bull (12%)+300%

Genomelink executes a credible clinical pivot via the T1D Scout / Basepair partnership, attracts a strategic acquirer (pharma R&D or health data aggregator) at $40-50M by 2030-2032. After clearing $9M in liquidation preferences, common holders realize roughly 5x gross on entry-valuation equity, compressed to ~300% net after an anticipated additional dilutive funding round.

Base (33%)-50%

The company remains subscale at 15 employees generating ~$1.3M in annual subscription revenue with no clear path to a liquidity event in the next 2-4 years. Any modest acquisition in the $10-15M range leaves employees with minimal or zero proceeds after the $9M preference stack is satisfied, and prolonged illiquidity erodes the real value of the equity grant by approximately 50%.

Bear (55%)-90%

Consumer genomics incumbents further commoditize trait analysis, user acquisition stagnates, and $1.3M in revenue is insufficient to sustain operations at 15 headcount without new capital — none raised since December 2021. The company is wound down or acqui-hired below the $9M preference stack threshold, leaving common stockholders (employees) with effectively zero recovery.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Funding Intensity

214%

~$9M in total liquidation preferences exceeds the current $4.2M valuation by 2.14x, meaning common shareholders receive zero in any exit at or below $9M.

Dilution Risk

high

With no funding since December 2021 and insufficient revenue to sustain growth at scale, the company will likely require additional dilutive financing before any liquidity event materializes.

Secondary Liquidity

none

At 15 employees and $1.3M in annual revenue with no disclosed secondary market activity, there is no practical mechanism for employees to monetize equity outside a full acquisition or IPO.

Questions to Ask at the Interview

Strategic questions based on Genomelink's data — designed to show you've done your homework.

  • 1

    “Given that total funding raised ($9M) exceeds the current estimated valuation ($4.2M) and no capital has been raised since December 2021, what is the current cash runway and what milestones trigger the next financing event?”

  • 2

    “What is the current paid subscriber count, month-over-month retention rate, and revenue trajectory over the last four quarters — and why has annual revenue growth rate not been publicly disclosed?”

  • 3

    “At what exit valuation would common stockholders begin to see positive returns after the $9M liquidation preference is satisfied, and has leadership modeled and shared these waterfall scenarios with the team?”

Community

Valuation Sentiment

Our model estimates -30% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.